ArticleOphthalmic research2026
A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Article in Ophthalmic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionMatching-adjusted network meta-analyses (NMAs) provide an established method to indirectly compare treatments across trials that share a common comparator. In this exploratory analysis, we conducted a matching-adjusted NMA to compare the efficacy of faricimab with aflibercept 8 mg for treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) via the common comparator of aflibercept 2 mg during the first 12 weeks of treatment when all agents are dosed equally.
methodsWeighting was applied to match patient populations from YOSEMITE/RHINE (NCT03622580/NCT03622593) and TENAYA/LUCERNE (NCT03823287/NCT03823300) based on their baseline characteristics to published aggregated baseline characteristics for PHOTON (NCT04429503) and PULSAR (NCT04423718), respectively. The matched populations were used to recalculate outcomes from faricimab trials and an NMA anchored to aflibercept 2 mg was conducted. The analysis focused on change in best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study letters and central subfield thickness (CST) in µm during the first 12 weeks of treatment when dosing was every 4 weeks for all three agents. Results are expressed as mean difference in change in BCVA or CST for each aflibercept dose.
resultsFor nAMD, BCVA change was similar between faricimab and aflibercept 2 mg and 8 mg, whereas CST reduction was greater for faricimab versus aflibercept 8 mg (-17.0 µm; 95% credible interval [CrI], -25.0, -8.4) and 2 mg (-19.0 µm; 95% CrI, -24.0, -13.0). For DME, BCVA change from baseline at 12 weeks was similar between faricimab and aflibercept 2 mg and 8 mg, while CST reduction was greater for faricimab versus aflibercept 8 mg (-19.0 µm; 95% CrI, -35.0, -3.2) and 2 mg (-19.0 µm; 95% CrI, -27.0, -12.0).
conclusionThis matching-adjusted NMA indicated that dual angiopoietin-2/vascular endothelial growth factor (VEGF)-A inhibition with faricimab was associated with greater retinal drying during the matched-dosing phase in patients with nAMD and DME. Early dual pathway inhibition may therefore improve outcomes beyond anti-VEGF monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.